Alzinova AB (publ) (FRA:78D)

Market Cap	9.24M -48.6%
Revenue (ttm)	2.34M +28.0%
Net Income	-2.42M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0446
Previous Close	0.0455
Day's Range	0.0446 - 0.0446
52-Week Range	0.0067 - 0.2510
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alz...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 78D

Financial Performance

In 2025, Alzinova AB's revenue was 26.80 million, an increase of 59.44% compared to the previous year's 16.81 million. Losses were -26.27 million, 27.8% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 21, 2026

Data Sources Report a data error